Ciproxin licensed for UTI in children

The licence for Ciproxin (ciprofloxacin) has been extended to include the second- and third-line treatment of complicated UTIs and pyelonephritis in children and adolescents aged between 1-17 years.

The dose is 10-20mg/kg orally every 12 hours up to a maximum of 750mg per dose. The recommended duration of treatment is 10-21 days.

View Ciproxin drug record

Further information: Bayer plc

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more